The impact of cerebrovascular disease on blood‐based biomarkers of Alzheimer's disease. (31st December 2021)

• Record Type: Journal Article
• Authors: Laing, Krystal K.; Lao, Patrick J.; Gutierrez, Jose; Sanchez, Danurys; Reyes‐Dumeyer, Dolly; Lantigua, Rafael A.; Honig, Lawrence S.; Airey, David C.; Manly, Jennifer J.; Dage, Jeffrey L.; Mayeux, Richard; Brickman, Adam M.
• Is Part Of: Alzheimer's & dementia. Volume 17(2021)Supplement 5
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-12-31
• Subjects: Alzheimer's disease -- Periodicals; Alzheimer Disease -- Periodicals; Dementia -- Periodicals; Démence; Maladie d'Alzheimer; Périodique électronique (Descripteur de forme); Ressource Internet (Descripteur de forme); 616.83
• DOI: 10.1002/alz.055434
• Languages: English
• ISSNs: 1552-5260

Abstract

Abstract: Background: The development of ultrasensitive assays for blood‐based biomarkers may allow for detection of Alzheimer's disease (AD)‐related pathology in large‐scale community‐based cohorts. We previously showed in the Washington Heights Inwood Columbia Aging Project (WHICAP) an association of plasma biomarker concentrations with clinical and pathological AD diagnosis, and that MRI markers of cerebrovascular disease, particularly parietal lobe white matter hyperintensities (WMH), increase the risk and progression of clinical AD. Here, we test the hypothesis that cerebrovascular disease has a direct impact on AD‐related pathology by examining the association of MRI markers of cerebrovascular disease and plasma biomarker concentrations in WHICAP. Method: Among 300 WHICAP participants with available structural MRI (mean age 81.87+ 6.45 years, 67% women, 33.3% non‐Hispanic white, 33.3% African American, 33.3% Hispanic, 42% with cognitive impairment) we used SIMOA and MSD technology to measure plasma concentrations of Aβ42, Aβ40, ptau181, ptau217, total tau, and NfL from banked plasma samples. MRI scans were analyzed for regional WMH, presence of infarct, and presence of microbleeds. We first examined bivariate correlations between MRI cerebrovascular measures and plasma biomarker concentrations. For markers that were associated, we conducted demographically adjusted analyses and examined interactions with cognitive diagnostic status. Result: Increased parietal lobe WMH, specifically, was associated with higher ptau181 (r=0.21, p=0.008) and ptau217 (r=0.13, p=0.05) concentrations. Increased WMH in frontal, temporal, and parietal regions was associated with increased NfL concentrations (rs=0.21‐0.25, ps<0.001‐0.002). Presence of one or more microbleed was associated with increased NfL (r=0.19, p=0.02). In adjusted models the associations of regional WMH with ptau181 and NfL concentrations were independent of and did not interact with diagnosis. Conclusion: Markers of small vessel cerebrovascular disease, particularly parietal lobe WMH, are associated with AD blood‐based biomarkers of phosphorylated tau pathology and neurodegeneration.